Coulter Partners successfully places Valerio Ferri as ExoLab Italia's new CEO

LONDON, UK, and MILAN, Italy, September 16, 2025 – Coulter Partners, the global expert in building leadership teams for Health, Science and Technology innovation businesses, is proud of the successful placement of Valerio Ferri as Chief Executive Officer (CEO) at ExoLab Italia.

ExoLab Italia is a biotech company producing plant-based exosomes for the cosmetics, nutraceutical, and pharmaceutical markets.

With extensive experience in the nutraceutical and pharmaceutical sectors, Valerio Ferri joins ExoLab Italia after holding senior roles in leading companies such as Biofarma Group, where he led the Sales & Marketing functions, bringing the group to a turnover of over 436 million euros, and Fidia Farmaceutici (where he developed the Contract Development Manufacturer – CDMO), contributing to significant growth. Additionally, he held a strategic role at Fareva, the world's second-largest CDMO manufacturer, strengthening his expertise in managing large global accounts and international growth. His background includes M&A, internationalization, and strategic development.

Valerio Ferri said:

I am thrilled to join ExoLab Italia at such a dynamic moment in its history. Plant-based exosomes represent an extraordinary frontier in biotechnological innovation, and I am confident that, thanks to the team's exceptional scientific and industrial know-how, we will be able to consolidate our leadership in Europe and expand globally.

Valerio Carconi, head of Sales & Marketing at ExoLab Italia further added:

Finding a leader with the precise combination of commercial acumen, technical expertise, and an understanding of our unique market was a significant challenge. Coulter Partners not only understood our specific needs but also expertly navigated the complexities of our location to find the perfect candidate. Their dedicated approach was instrumental in securing Valerio for this pivotal role.